Aldosterone synthase inhibitor
- ↓ aldosterone production at its source (CYP11B2)
- ↓ sodium retention and ↑ potassium retention → blood-pressure lowering in resistant hypertension
- Hyperkalemia is the principal mechanism-linked risk
- Selectivity over CYP11B1 spares cortisol
- Lowers aldosterone synthesis in resistant hypertension
- Hyperkalemia; cortisol selectivity is the design challenge
Drugs with this mechanism (1)
- Baxdrostat — First-in-class aldosterone synthase inhibitor for resistant hypertension.
All mechanisms · Open Aldosterone synthase inhibitor in the interactive console ↗